Sponsor or institution

Clinical trials and research at UCB Pharma

• 15Clinical trials
• 31Countries

Newest trials

All recruiting trials (15)

• Galvokimig for COPD with Chronic Bronchitis: 24 to 52 Weeks of Treatment

  This study tests whether Galvokimig helps reduce COPD flare-ups compared with placebo in adults 40–80 with moderate-to-severe COPD and chronic bronchitis.

  Recruiting at 26 sites Phase 2 UCB Pharma · Encino, California and 25 other locations · NCT07725939

• Galvokimig vs placebo for non-CF bronchiectasis in adults

  This study tests whether Galvokimig can delay the first pulmonary flare compared with placebo in adults with non-CF bronchiectasis.

  Recruiting at 7 sites Phase 2 UCB Pharma · Newport Beach, California and 6 other locations · NCT07720375

• SLC6A1-NDD: A Longitudinal Look at How the Disorder Progresses

  This study follows children and young people with SLC6A1-NDD over two years to see how the condition changes over time and to test which assessments work for future research.

  Recruiting at 3 sites UCB Pharma · New York, New York and 2 other locations · NCT07531511

• Fenfluramine HCl for Rett Syndrome in a Phase 3 study

  This study tests whether fenfluramine hydrochloride helps people with Rett syndrome when compared to a placebo.

  Recruiting at 40 sites Phase 3 UCB Pharma · Little Rock, Arkansas and 39 other locations · NCT07503444

• Rozanolixizumab for long-term safety and efficacy in adult ocular myasthenia gravis

  This study tests whether Rozanolixizumab is safe and helps adults with ocular myasthenia gravis over the long term.

  Recruiting at 18 sites Phase 3 UCB Pharma · Scottsdale, Arizona and 17 other locations · NCT07465289

• Rozanolixizumab for adult ocular myasthenia gravis

  This trial tests Rozanolixizumab versus placebo to see if it helps adults with ocular myasthenia gravis see improvements in eye muscles with tolerable safety.

  Recruiting at 36 sites Phase 3 UCB Pharma · Scottsdale, Arizona and 35 other locations · NCT07463521

• Bimekizumab by IV infusion versus subcutaneous injection for adults with psoriatic arthritis or axial spondyloarthritis

  This trial tests whether bimekizumab given by intravenous (IV) infusion behaves the same in the body as the usual subcutaneous injection in adults with psoriatic arthritis or axial spondyloarthritis.

  Recruiting at 65 sites Phase 1 UCB Pharma · Peoria, Arizona and 64 other locations · NCT07290036

• Bimekizumab for palmoplantar pustulosis (PPP)

  This trial tests whether bimekizumab helps adults with palmoplantar pustulosis and is safe compared with a placebo.

  Recruiting at 91 sites Phase 3 UCB Pharma · Birmingham, Alabama and 90 other locations · NCT07219420

• Measure zilucoplan concentration in breast milk of healthy lactating women.

  This test gives daily zilucoplan injections to healthy lactating women who plan to stop breastfeeding to see how much the drug and its metabolites appear in mature breast milk.

  Recruiting at 2 sites Phase 1 UCB Pharma · San Antonio, Texas and 1 other locations · NCT06961747

• Assessing Bimekizumab Levels in Breast Milk of Nursing Mothers

  This study tests how much of the medication bimekizumab is found in the breast milk of mothers who have been using it for at least 12 weeks after giving birth to see if it's safe for their babies.

  Recruiting at 14 sites Phase 1 UCB Pharma · Santa Monica, California and 13 other locations · NCT06888193

• Evaluating Bimekizumab for Pediatric Arthritis

  This study is testing a new medication called bimekizumab in children with certain types of arthritis to see if it is safe and effective for them.

  Recruiting at 21 sites Phase 3 UCB Pharma · Calgary and 22 other locations · NCT06668181

• Evaluating Dapirolizumab Pegol for Active Systemic Lupus Erythematosus

  This study is testing if adding a new treatment called dapirolizumab pegol can help people aged 16 and older with active lupus feel better while they are already on standard medications.

  Recruiting at 238 sites Phase 3 UCB Pharma · Avondale, Arizona and 244 other locations · NCT06617325

• Evaluating Zilucoplan for Pediatric Myasthenia Gravis

  This study is testing a new medication called zilucoplan to see how it works and if it's safe for children aged 2 to 18 with generalized myasthenia gravis.

  Recruiting at 5 sites Phase 2/3 UCB Pharma · Chicago, Illinois and 8 other locations · NCT06055959

• Testing Staccato Alprazolam for Prolonged Seizures in Patients 12 and Older

  This study is testing if a new inhaled medication called Staccato alprazolam can quickly stop prolonged seizures in people aged 12 and older and keep them from coming back for a short time.

  Recruiting at 125 sites Phase 3 UCB Pharma · Phoenix, Arizona and 182 other locations · NCT05077904

• Brivaracetam safety and tolerability in children and teens with seizures

  We will test if long-term brivaracetam is safe and well tolerated for children and adolescents with epilepsy, including those from prior pediatric brivaracetam studies and children in Japan with focal seizures.

  Recruiting at 6 sites Phase 3 UCB Pharma · Hawthorne, New York and 35 other locations · NCT04715646

Quick answers

How many clinical trials run by UCB Pharma are recruiting right now?

15, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 31 countries. The most sites are in United States (14 trials), Poland (10 trials), Spain (10 trials), France (9 trials), Germany (9 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 8, Phase 1: 3, Phase 2: 2, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →